Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
SRI-37330
Cat. No.:
OB0425LY-132
Appearance:
Solid
Purity:
99.16%
Identity:
Confirmed by NMR and LC-MS.
Size:
Add to basket
Product Overview
Description:
SRI-37330 is a thioredoxin-interacting protein (TXNIP) inhibitor that nhibits glucagon secretion and function.
Synonyms:
2322245-42-9; N-((1-(6-(Trifluoromethyl)quinazolin-4-yl)piperidin-3-yl)methyl)methanesulfonamide; N-[[1-[6-(Trifluoromethyl)quinazolin-4-yl]piperidin-3-yl]methyl]methanesulfonamide;
CAS No.:
2322245-42-9
Compound CID:
142582737
Formula:
C16H19F3N4O2S
Formula Weight:
388.41
Specification
Target:
Arrestin
Pathway:
GPCR/G protein
Solubility:
DMSO
Storage:
Storage at 4°C.
Applications:
SRI-37330 is mainly used in the study of metabolism-related diseases, especially in diabetes mellitus.
